Current Medical Science

, Volume 39, Issue 1, pp 75–80 | Cite as

Decrease of GSK3β Ser-9 Phosphorylation Induced Osteoblast Apoptosis in Rat Osteoarthritis Model

  • Shuang Deng
  • Zhi-gang Nie
  • Pu-ji Peng
  • Yang Liu
  • Sai Xing
  • Lin-sheng Long
  • Hao PengEmail author


Nowadays, the cumulative intake of glucocorticoids has become the most common pathogenic factor for non-traumatic osteonecrosis of the femoral head (ONFH). Apoptosis of osteoblasts is considered as the main reason of ONFH at the molecular level. Glycogen synthase kinase 3β (GSK3β) is an important regulator of cellular differentiation and apoptosis pathway, which can modulate the balance between osteoblasts and osteoclasts. Several studies have reported about its function in osteoporosis, but little is known about it in osteonecrosis. In our study, lipopolysaccharide and methylprednisolone were utilized to establish a rat ONFH model. The phosphorylation of GSK3β Ser-9 was decreased in the model. Western blotting examination of β-catenin, Bcl-2, Bax and caspase-3 revealed that the osteoblasts were apoptotic. In dexamethasone (Dex)-incubated primary osteoblasts, the expression profile of GSK3β phosphorylation and apoptotic factors were consistent with those in the rat ONFH model. To further investigate the regulation of osteonecrosis caused by GSK3β, the expression and function of GSK3β were inhibited in Dex-incubated primary osteoblasts. The knockdown of GSK3β by siRNA decreased the expression of Bax and cleaved caspase-3, but increased Bcl-2 and β-catenin. On the other hand, selective inhibition of GSK3β function by LiCl counteracted the activation of caspase-3 induced by Dex. Our work is the first study about the GSK3β phosphorylation in ONFH, and provides evidence for further therapeutic methods.

Key words

osteonecrosis of the femoral head GSK3β phosphorylation apoptosis dexamethasone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gessi S, Merighi S, Borea PA. Glucocorticoid’s pharmacology: past, present and future. Curr Pharm Des, 2010,16(32):3540–3553CrossRefGoogle Scholar
  2. 2.
    Yang Z, Liu H, Li D, et al. The efficacy of statins in preventing glucocorticoid–related osteonecrosis in animal models: A meta–analysis. Bone Joint Res, 2016,5(9):393–402CrossRefGoogle Scholar
  3. 3.
    Zheng H, Yang E, Peng H, et al. Gastrodin prevents steroid–induced osteonecrosis of the femoral head in rats by anti–apoptosis. Chin Med J, 2014,127(22):3926–3931Google Scholar
  4. 4.
    Weinstein RS. Glucocorticoid–induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am, 2012,41(3):595–611CrossRefGoogle Scholar
  5. 5.
    Zalavras C, Shah S, Birnbaum MJ, et al. Role of apoptosis in glucocorticoid–induced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene, 2003,13(2–4):221–235Google Scholar
  6. 6.
    Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase–3. Trends Biochem Sci, 2004,29(2):95–102CrossRefGoogle Scholar
  7. 7.
    Yun SI, Yoon HY, Jeong SY, et al. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab, 2009,27(2):140–148CrossRefGoogle Scholar
  8. 8.
    Guo B, Zhang W, Xu S, et al. GSK–3beta mediates dexamethasone–induced pancreatic beta cell apoptosis. Life Sci, 2016,144:1–7CrossRefGoogle Scholar
  9. 9.
    Spokoini R, Kfir–Erenfeld S, Yefenof E, et al. Glycogen synthase kinase–3 plays a central role in mediating glucocorticoid–induced apoptosis. Mol Endocrinol, 2010,24(6):1136–1150CrossRefGoogle Scholar
  10. 10.
    Hughes K, Nikolakaki E, Plyte SE, et al. Modulation of the glycogen synthase kinase–3 family by tyrosine phosphorylation. EMBO J, 1993,12(2):803–808CrossRefGoogle Scholar
  11. 11.
    Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. P Natl Acad Sci USA, 1996,93(16):8455–8459CrossRefGoogle Scholar
  12. 12.
    Eldar–Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med, 2002,8(3):126–132CrossRefGoogle Scholar
  13. 13.
    Martinez A, Castro A, Dorronsoro I, et al. Glycogen synthase kinase 3 (GSK–3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev, 2002,22(4):373–384CrossRefGoogle Scholar
  14. 14.
    Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3–kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta–catenin accumulation. J Biol Chem, 2002,277(34):30 935–30 941CrossRefGoogle Scholar
  15. 15.
    Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase–3beta in endoplasmic reticulum stress–induced caspase–3 activation. J Biol Chem, 2002,277(47):44 701–44 708CrossRefGoogle Scholar
  16. 16.
    Jin ZH, Kurosu T, Yamaguchi M, et al. Hematopoietic cytokines enhance Chk1–dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene, 2005,24(12):1973–1981CrossRefGoogle Scholar
  17. 17.
    Zhang C, Zou YL, Ma J, et al. Apoptosis associated with Wnt/beta–catenin pathway leads to steroid–induced avascular necrosis of femoral head. BMC Musculoskel Dis, 2015,16:132CrossRefGoogle Scholar
  18. 18.
    Smith E, Coetzee GA, Frenkel B. Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase–3beta. J Biol Chem, 2002,277(20):18 191–18 197CrossRefGoogle Scholar
  19. 19.
    Okazaki S, Nishitani Y, Nagoya S, et al. Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll–like receptor 4 signalling pathway. Rheumatology, 2009,48(3):227–232CrossRefGoogle Scholar
  20. 20.
    Li H, Qian W, Weng X, et al. Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3–E1 cells. PLoS one, 2012,7(6):e37 030CrossRefGoogle Scholar
  21. 21.
    Li J, He C, Tong W, et al. Tanshinone IIA blocks dexamethasone–induced apoptosis in osteoblasts through inhibiting Nox4–derived ROS production. Int J Clin Exp Patho, 2015,8(10):13 695–13 706Google Scholar
  22. 22.
    Sato AY, Tu X, McAndrews KA, et al. Prevention of glucocorticoid induced–apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice. Bone, 2015,73:60–68CrossRefGoogle Scholar
  23. 23.
    Beurel E, Jope RS. The paradoxical pro–and antiapoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol, 2006,79(4):173–189CrossRefGoogle Scholar
  24. 24.
    Akhtar RS, Ness JM, Roth KA. Bcl–2 family regulation of neuronal development and neurodegeneration. BBAMol Cell Res, 2004,1644(2–3):189–203Google Scholar
  25. 25.
    Bijur GN, Jope RS. Glycogen synthase kinase–3 beta is highly activated in nuclei and mitochondria. Neuroreport, 2003,14(18):2415–2419CrossRefGoogle Scholar
  26. 26.
    Watcharasit P, Bijur GN, Song L, et al. Glycogen synthase kinase–3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem, 2003,278(49):48 872–48 879CrossRefGoogle Scholar
  27. 27.
    Guidotti S, Minguzzi M, Platano D, et al. Lithium Chloride Dependent Glycogen Synthase Kinase 3 Inactivation Links Oxidative DNA Damage, Hypertrophy and Senescence in Human Articular Chondrocytes and Reproduces Chondrocyte Phenotype of Obese Osteoarthritis Patients. PLoS One, 2015,10(11):e0143 865CrossRefGoogle Scholar
  28. 28.
    Li H, Huang K, Liu X, et al. Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK–3beta/NF–kappaB signaling pathway. Oxid Med Cell Longev, 2014,2014:241 864Google Scholar

Copyright information

© Huazhong University of Science and Technology 2019

Authors and Affiliations

  • Shuang Deng
    • 1
  • Zhi-gang Nie
    • 1
  • Pu-ji Peng
    • 1
  • Yang Liu
    • 1
  • Sai Xing
    • 1
  • Lin-sheng Long
    • 1
  • Hao Peng
    • 1
    Email author
  1. 1.Department of OrthopedicsRenmin Hospital of Wuhan UniversityWuhanChina

Personalised recommendations